Company: PGEN
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001356090-25-000024
Chunk: 14

Company: PRECIGEN, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 of June 30, 2025 and $79,000 as of December 31, 2024).30,883 28,218 Shareholders' equity (deficit)Common stock, no par value, 400,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 297,846,160 shares and 292,869,097 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively.— — Additional paid-in capital2,134,711 2,129,207 Accumulated deficit(2,171,501)(2,090,706)Accumulated other comprehensive income11 12 Total shareholders' (deficit) equity (36,779)38,513 Total liabilities, mezzanine equity and shareholders' (deficit) equity$101,896 $145,266 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

Precigen, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(Amounts in thousands, except share and per share data)Three Months Ended  June 30,Six Months Ended  June 30,2025202420252024RevenuesProduct revenues$41 $31 $244 $169 Service revenues781 673 1,896 1,592 Other revenues34 13 57 21 Total revenues856 717 2,197 1,782 Operating ExpensesCost of products and services1,092 1,014 2,192 2,089 Research and development11,488 15,693 21,966 29,942 Selling, general and administrative16,133 10,306 28,492 20,457 Impairment of goodwill3,907 1,630 3,907 1,630 Impairment of other noncurrent assets— 32,915 — 32,915 Total operating expenses32,620 61,558 56,557 87,033 Operating loss(31,764)(60,841)(54,360)(85,251)Other Income (Expense), NetChange in fair value of warrant liabilities4,460 — (28,021)— Interest expense— (2)(1)(4)